GlassScriptPhysician profile
Christopher V Crosby
NPI 1497931380
$3,875.78
in general payments reported to CMS, 2019-2025
34 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $93.83 · 2021: $299 · 2022: $595 · 2023: $595 · 2024: $953 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,398 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,397.92 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $566.12 | 2023-2025 | Tremfya |
| Abbvie INC. | $495.28 | 2019-2025 | |
| Genzyme Corporation | $449.62 | 2022-2025 | |
| Merz North America, INC. | $408.28 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $351.02 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $230.40 | 2023-2024 | Sotyktu |
| Medline Industries LP | $136.91 | 2023-2025 | |
| Incyte Corporation | $122.47 | 2023-2024 | Opzelura |
| Leo Pharma INC. | $85.50 | 2024-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $81.81 | 2020-2021 | |
| Organogenesis INC. | $79.16 | 2023-2024 | Puraply |
| Genentech USA, INC. | $76.86 | 2019 | |
| Almirall LLC | $76.47 | 2019-2024 | Klisyri |
| Ucb, INC. | $72.87 | 2024-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.99 | 2022-2024 | Spevigo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63.96 | 2021-2024 | Taltz, Olumiant |
| Pfizer INC. | $60.35 | 2019-2025 | |
| Dermavant Sciences, INC. | $57.61 | 2024 | Vtama |
| Prugen, INC. Pharmaceuticals | $56.76 | 2019 | |
| Revance Therapeutics, INC. | $48.46 | 2024 | Daxxify |
| Dusa Pharmaceuticals, INC. | $44.27 | 2019 | |
| Galderma Laboratories, L.P. | $37.77 | 2024 | |
| Strata Skin Sciences, INC. | $30.80 | 2024 | Xtrac |
| Amgen INC. | $26.79 | 2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.09 | 2021 | |
| Allergan, INC. | $24.97 | 2022 | |
| Celgene Corporation | $18.94 | 2019 | |
| Apyx Medical Corporation | $18.61 | 2020 | |
| Stemline Therapeutics INC. | $17.07 | 2021 | |
| Sensus Healthcare, INC. | $16.00 | 2019 | |
| Epi Health, LLC | $15.48 | 2019 | |
| Biofrontera INC. | $15.09 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Crosby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.